Umang Swami, Oncologist at Huntsman Cancer Institute, University of Utah, shared a post on X about a recent paper titled “Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States” published in Future Oncology.
Authors: Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar and Sumati Gupta.
“Just in Future Oncology. One of the largest real world studies evaluating TRT trends in nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common TRT.”
Source: Umang Swami/X
